The coronavirus (CoV) that causes severe acute respiratory syndrome, or SARS, is called SARS-CoV. CoVs, which are enveloped viruses with positive-sense, single-stranded RNA and can target the human respiratory system to spread disease, include not only the SARS virus but also MERS and SARS-CoV-2, which is the source of COVID-19.
The spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are the four main structural proteins of CoVs. By binding to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), an S protein mediates the CoV entry into host cells, which is followed by the fusion of the virus and host cell membranes. Following entry, a large number of nonstructural proteins, including Mpro (main protease or 3CLpro), PLpro (papain-like protease), and RdRp (RNA-dependent RNA polymerase), participate in genome replication and subgenomic RNA transcription.The structural proteins are then translated, put together into mature virions, and exocytosed to release them via vesicles. It is noteworthy that a protease known as TMPRSS2 (transmembrane protease, serine 2), which cleaves S protein, plays crucial roles throughout the entire life of CoVs (such as attachment, assembling, and release). For the treatment of diseases brought on by CoVs, all the proteins and subcellular structures involved in the life cycle of CoVs are promising targets.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V78860 | COVID-19 Spike Protein mRNA-LNP | COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing COVID-19 spike protein, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. | |
|
V84453 | Covidcil-19 | 1225177-95-6 | |
|
V76094 | Crexavibart (BMS-986413; C-144-LS) | 2599039-61-7 | Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain. |
|
V86311 | CTSL/B-IN-1 | ||
|
V78997 | D-4-77 | D-4-77 is a potent inhibitor of SARS-CoV-2 Mpro with IC50 of 0.95 μM. | |
|
V76088 | D1N52 | 2894770-48-8 | D1N52 is a potent SARS-CoV-2 3CLpro inhibitor (antagonist) with IC50 of 0.53 μM. |
|
V76078 | D1N8 | 2894770-40-0 | D1N8 is a potent SARS-CoV-2 3CLpro inhibitor (antagonist) with IC50 and CC50 values of 0.44 μM and >20 μM, respectively. |
|
V85797 | Danshensu sodium (Dan shen suan A sodium; Salvianic acid A sodium) | 81075-52-7 | |
|
V54379 | Daxdilimab (MEDI7734; VIB7734) | 2245966-28-1 | Daxdilimab is an anti-ILT7 monoclonal antibody (mAb), a cell surface molecule unique to pDC-type dendritic cells. |
|
V54437 | Debrisoquin (Debrisoquine; Isocaramidine; Ro 5-3307/1) | 1131-64-2 | Debrisoquin (Isocaramidine) is a TMPRSS2 inhibitor that can suppress SARS-CoV-2 entry into human lung cell lines in a TMPRSS2-dependent manner with IC50 of 22 μM. |
|
V52800 | Dexamethasone-d5 (Hexadecadrol-d5; Prednisolone F-d5) | 358731-91-6 | Dexamethasone-d5 is the deuterated form of Dexamethasone. |
|
V79136 | Dihydromaniwamycin E | Dihydromaniwamycin E is a heat shock metabolite with anti-viral effect against influenza and SARS-CoV-2 viruses. | |
|
V29003 | Dihydrotanshinone I | 87205-99-0 | Dihydrotanshinone I is a naturally occuring phenanthrene-quinone found in Salvia miltiorrhiza Bunge that has been widely used for treating cardiovascular diseases. |
|
V79233 | E07 aptamer | SARS-CoV-2 nsp14-IN-4 (Compound 12q) is a selective inhibitor of SARS-CoV-2 nsp14 methyltransferase with IC50 of 19 ± 2.5 nM. | |
|
V39191 | EIDD-1931 (Beta-d-N4-hydroxycytidine; NHC) | 3258-02-4 | EIDD-1931(EIDD1931; Beta-d-N4-hydroxycytidine; NHC) is anovel and potentribonucleoside analog with antiviral activity. |
|
V52132 | EIDD-2749 (4'-FlU; 4'-Fluorouridine) | 1613589-24-4 | EIDD-2749 (4'-Fluorouridine) is an orally bioavailable RdRp inhibitor. |
|
V85205 | Elopiprazole | 115464-77-2 | |
|
V54387 | Enibarcimab | 2305638-98-4 | Enibarcimab is a humanized mouse monoclonal immunoglobulin G1 (IgG1) antibody utilized in the research of acute heart failure, COVID 2019 infection and septic shock. |
|
V3351 | Ensitrelvir | 2647530-73-0 | Ensitrelvir (also known as S-217622; trade name Xocova) is an orally bioavailable, non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM) effective against the Omicron variant. |
|
V60009 | Ensitrelvir fumarate | 2757470-18-9 | Ensitrelvir fumarate (S-217622 fumarate; Xocova) is a novel and orally bioavailable SARS-CoV-2 3CL protease inhibitor (IC50=13 nM) approval in Japanunder the emergency regulatory approval system (EUA) for COVID-19 treatment. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
